Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* Treatment of patients with acute coronary syndrome (ACS).
* Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) with or without prior percutaneous coronary intervention (PCI).
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or longer if tolerated and indicated.
* For patients who are not adequately managed with oral antiplatelet therapy and have a higher risk of bleeding, a lower maintenance dose of 60 mg orally twice daily can be considered after the first year of treatment.
* **History of MI (at least 1 year post-MI):**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
The safety and efficacy of ticagrelor in pediatric patients have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is recommended in patients with mild to moderate hepatic impairment. Caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including serious and life-threatening), bradyarrhythmia.
* **Other:** Ventricular pauses, transient increases in serum creatinine, hyperkalemia.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor inhibits CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase ticagrelor concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor concentrations.
* **P-glycoprotein (P-gp) Substrates:** Ticagrelor inhibits P-gp. Concomitant use with P-gp substrates (e.g., digoxin) may increase concentrations of the P-gp substrate.
* **Other Antiplatelet Agents and Anticoagulants:** Increased risk of bleeding. Use with caution.
* **Aspirin:** While indicated for use with aspirin, higher doses of aspirin may reduce the efficacy of ticagrelor.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor serum creatinine, particularly in patients with renal impairment or those taking other drugs that affect renal function.
* Monitor potassium levels, especially in patients with risk factors for hyperkalemia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect can be reversed more quickly than clopidogrel if urgent surgery is required.
* Dyspnea is a common side effect and is usually not associated with underlying pulmonary disease. It typically resolves with continued treatment.
* The maintenance dose for ACS is typically 90 mg BID, but can be reduced to 60 mg BID after 1 year for certain patients.
* The maintenance dose for patients with a history of MI (at least 1 year post-MI) is 60 mg BID.
* Ticagrelor should be taken with or without food.
* Avoid concomitant use with strong CYP3A4 inhibitors or inducers unless clinically necessary.
---
***Disclaimer:** This information is intended for healthcare professionals and does not replace the need for professional judgment. Always consult the official prescribing information and relevant clinical guidelines for complete and up-to-date information before making any treatment decisions.*
